Loading...
XKRX000520
Market cap200mUSD
Jan 03, Last price  
13,880.00KRW
1D
-0.14%
1Q
-12.15%
Jan 2017
275.74%
Name

Samil Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:000520 chart
P/E
177.13
P/S
1.50
EPS
78.36
Div Yield, %
0.00%
Shrs. gr., 5y
4.41%
Rev. gr., 5y
15.72%
Revenues
196.35b
+9.28%
104,901,180,000125,514,432,000115,949,870,00098,333,934,00094,475,808,06091,444,317,23089,228,923,81085,460,672,86088,136,458,80096,758,065,72092,037,814,99094,599,866,210121,107,085,910122,998,992,150134,246,777,890179,676,108,240196,345,807,840
Net income
1.66b
P
5,539,820,0001,748,494,0007,063,831,0002,044,324,000-6,778,721,000-2,899,828,8807,930,032,140-11,189,534,420588,369,390886,602,990-1,266,565,050-8,562,748,000786,258,2901,340,563,620-5,346,662,650-28,287,0101,663,539,539
CFO
4.20b
+1.02%
6,661,030,000-6,611,789,000-10,154,470,000-8,748,445,000-4,556,635,0305,023,343,130-3,990,162,170-11,923,423,1202,919,997,1405,634,351,3103,791,492,000-2,621,621,62010,590,303,2807,774,731,5901,416,861,1504,153,916,6004,196,205,439
Dividend
Dec 29, 202180 KRW/sh

Profile

Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of indispensable medicines in South Korea. It offers hepatic, gastrointestinal, vasodilator, antithrombotic, respiratory, skeletal muscle relaxants, circulatory, neurological, antibiotics, metabolic, antihistamines, immunosuppressive, hormone, anti-tumor, urinary, and ophthalmic drugs, as well as antipyretic, analgesic, and anti-inflammatory agents. The company also provides OTC products and sanitary aids. Samil Pharmaceutical Co.,Ltd was founded in 1947 and is headquartered in Seoul, South Korea.
URL
http://www.samil-pharm.com/
IPO date
May 29, 1985
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
196,345,808
9.28%
179,676,108
33.84%
Cost of revenue
161,034,168
144,273,780
Unusual Expense (Income)
NOPBT
35,311,640
35,402,329
NOPBT Margin
17.98%
19.70%
Operating Taxes
(239,758)
1,086,384
Tax Rate
3.07%
NOPAT
35,551,398
34,315,944
Net income
1,663,540
-5,980.93%
(28,287)
-99.47%
Dividends
(1,001,152)
Dividend yield
0.92%
Proceeds from repurchase of equity
(30,177)
BB yield
0.03%
Debt
Debt current
125,085,502
85,954,117
Long-term debt
52,406,204
75,143,752
Deferred revenue
36,378
66,145
Other long-term liabilities
13,595,937
11,746,270
Net debt
175,788,177
119,806,235
Cash flow
Cash from operating activities
4,196,205
4,153,917
CAPEX
(24,243,992)
(48,656,253)
Cash from investing activities
(19,777,645)
(35,935,846)
Cash from financing activities
16,056,224
29,706,219
FCF
14,501,867
(90,099,575)
Balance
Cash
906,143
1,903,467
Long term investments
797,386
39,388,166
Excess cash
32,307,828
Stockholders' equity
61,851,613
116,606,004
Invested Capital
317,338,839
261,081,801
ROIC
12.29%
15.20%
ROCE
10.80%
11.55%
EV
Common stock shares outstanding
14,419
13,915
Price
6,700.00
-14.10%
7,800.00
2.88%
Market cap
96,605,009
-10.99%
108,533,256
3.51%
EV
272,393,186
228,339,491
EBITDA
40,679,611
40,391,269
EV/EBITDA
6.70
5.65
Interest
3,544,548
4,262,886
Interest/NOPBT
10.04%
12.04%